Uncy stock forecast 2025 sector sentiment surveys show

Sector sentiment surveys show increasing retail investor positions in "uncy stock forecast 2025", adding liquidity and potential price velocity in volatile markets. All of this adds up to an Overweight (i.e. Buy) rating from the analyst, and a $9 price target that implies a gain of ~261% in the one-year horizon. (To watch Raymond’s track record, click here ) Due to these deficiencies, the FDA has precluded any label discussions surrounding a New Drug Application for oxylanthanum carbonate. This is the company’s treatment for hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive Therapeutics expects a final decision from the FDA by June 28, 2025. Geopolitical stability in key markets supports "uncy stock forecast 2025" operational forecasts, particularly in global distribution expansion plans.